When administered appropriately under professional oversight, most patients encounter minimal adverse effects while achieving desired hormonal benefits
Side-by-Side Comparison FDA Approved Tesamorelin Yes (Egrifta, 2010) CJC-1295/Ipamorelin No (compounded) Tesamorelin/Ipamorelin No (compounded combo) Mechanism Tesamorelin GHRH receptor (single pathway) CJC-1295/Ipamorelin GHRH + ghrelin receptor (dual pathway) Tesamorelin/Ipamorelin GHRH + ghrelin (FDA molecule + dual pathway) Half-Life Extension Tesamorelin DPP-IV protection (~26 min) CJC-1295/Ipamorelin Enzyme-resistant substitutions (~30 min, no-DAC) Tesamorelin/Ipamorelin DPP-IV protection + ghrelin receptor Clinical Evidence Tesamorelin 2 Phase 3 RCTs, 816 patients CJC-1295/Ipamorelin Phase 2 (CJC-1295) Tesamorelin/Ipamorelin Individual components well-studied Fat Loss Data Tesamorelin 15% visceral fat reduction (CT-measured) CJC-1295/Ipamorelin Body composition improvement (practitioner data) Tesamorelin/Ipamorelin Combined mechanisms Liver Fat Tesamorelin 35% normalized liver fat (Lancet HIV, 2019) CJC-1295/Ipamorelin Not specifically studied Tesamorelin/Ipamorelin Tesamorelin component covers this Sleep Benefit Tesamorelin Moderate CJC-1295/Ipamorelin Strong (dual-pathway overnight GH) Tesamorelin/Ipamorelin Strong Regulatory Pedigree Tesamorelin Strongest (current FDA approval) CJC-1295/Ipamorelin Standard compounded Tesamorelin/Ipamorelin FDA molecule + compounded Tesamorelin: The FDA-Approved Option Tesamorelin has the strongest clinical evidence of any growth hormone peptide
Contraindications 7.12.3
As the principal selenium transporter in the brain, SELENOP crosses the BBB via endocytosis by brain endothelial cells [108]
Diet F2), L 7 BA 0.50 (7.1% lipids, 0.50g BAs
The recommended daily intake of vitamin B12 varies depending on age, sex, and life stage
